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Abstract
hTERTC27 is a newly constructed polypeptide that can induce telomere dysfunction. To study the synergistic
antitumor effects of the hTERTC27 polypeptide driven by the early growth response protein-1 (Egr-1) promoter
and chemotherapeutic 5-ﬂurorouracil (5-FU) on nasopharyngeal carcinoma, a series of in vitro and in vivo
experiments were performed. The results showed that hTERTC27 expression was signiﬁcantly increased up to
7.21-folds by the 5-FU-activated Egr-1 promoter in C666-1 cells. Overexpressed hTERTC27 made the cells more
sensitive to 5-FU, and additionally, inhibited cell proliferation about 20.41%. Combinational therapy of over-
expressed hTERTC27 driven by the 5-FU-activated Egr-1 promoter and 5-FU synergistically inhibited cell pro-
liferation and promoted apoptosis of C666-1 cells for about 4.75-fold and 1.76-fold in comparison with a sole
therapy of hTERTC27 or 5-FU in vitro. In vivo experiments showed that overexpressed hTERTC27 driven by
5-FU-activated Egr-1 promoter and 5-FU synergistically reduced tumor volume, tumor weight, and local inﬁl-
tration, which may be relative to tumor cell apoptosis. These results suggest that combinational therapy of
overexpressed hTERTC27, which is driven by the 5-FU-activated Egr-1 promoter, and 5-FU may provide a novel
approach to treat nasopharyngeal cancer.
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Introduction
Nasopharyngeal carcinoma (NPC) is one of the mostmalignant neoplasms in the nasopharynx, especially in
Southeastern Asia. 5-ﬂuorouracil (5-FU), the most widely
used anticancer agent, has been applied widely to the treat-
ment of NPC.1,2 However, 5-FU treatment has only limited
beneﬁt to the NPC patients because of severe side effects
caused by high dosage and failing preventing recurrence and
metastasis due to limited sensitivity.3 Therefore, several strategies
of gene therapy have been intensively explored to treat NPC.4,5
Telomerase is an attractive target for cancer gene ther-
apy, because it is highly active in most cancer cells, but it
is inactive in most somatic cells.6 The primary function of
telomerase is to maintain the telomere length and to pro-
long the life span of cells.7 The dysfunction of telomerase
will prevent the long-term survival of tumor cells and lead to
cell death or senescence.8,9 Telomerase reverse transcriptase
(TERT), the catalytic protein subunit of telomerase, is criti-
cal for the activity of telomerase in tumor cells.10 Previously,
we have reported that a 27-kDa C-terminal polypeptide
of hTERT (hTERTC27) is capable of inducing telomere
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dysfunctions, and overexpression of hTERTC27 in human
cervical carcinoma HeLa cells slows down the cell prolifer-
ation and inhibits the tumorigenicity by signiﬁcantly in-
creasing anaphase chromosome end-to-end fusion.11 Ectopic
overexpression of this polypeptide also makes the HeLa cells
more sensitive to H2O2-induced oxidative injury.
12 Further-
more, hTERTC27 delivered by recombinant adeno-associated
virus or recombinant adeno-associated virus and adenovirus
cocktail system suppresses tumor growth in vivo in a human
U87-MG glioblastoma xenograft model.13,14
The early growth response protein-1 (Egr-1) promoter,
which is sensitive to reactive oxygen intermediates,15 is
commonly used as a bridge in gene therapy, because it can
be activated by oxygen free radicals generated by radio-
therapy or chemotherapy and promotes the high expression
of tumor therapeutic genes.16,17 Therefore, we hypothesize
that the radical agent 5-FU may activate the Egr-1 promoter,
which can drive the overexpression of hTERTC27 that makes
tumor cells sensitive to the chemotherapy of 5-FU, and have
the chemotherapeutic effect on NPC.
In this study, hTERTC27 cDNA was constructed to the
downstream of the Egr-1 promoter, which was transfected
into the C666-1 cells. The synergistic antitumor effects of
the 5-FU and hTERTC27 polypeptide driven by the 5-FU-
activated Egr-1 promoter were assayed for the ﬁrst time.
Overexpressed hTERTC27 driven by the Egr-1 promoter
made the C666-1 cells more sensitive to 5-FU and synergis-
tically inhibited C666-1 cell proliferation and induced
apoptosis with 5-FU treatment. These results suggest that the
synergistic effect of 5-FU and Egr-1 promoter-driven
hTERTC27 might be a potential clinical strategy for naso-
pharyngeal cancer therapy.
Materials and Methods
Cell culture
Human NPC C666-1 cells were maintained in our lab and
cultured in the Dulbecco’s modiﬁed Eagle’s medium
(DMEM; Hyclone), supplemented with 10% fetal bovine
serum (FBS; Hyclone), 100 lg/mL penicillin (Ameresco), and
100 lg/mL streptomycin (Ameresco). Cells were cultured at
37C in a humidiﬁed atmosphere with 5% CO2.
Plasmid construction and transfection
The pcDNA3.1-Egr-1 plasmid (pEgr) was a gift from
Dr. Jianxiang Liu and Mei Tian. In this plasmid, the cyto-
megalovirus promoter was substituted with the Egr-1 pro-
moter. cDNAs of a 27-kDa hTERT C-terminal polypeptide
(hTERTC27, amino acid residues 882–1132) and enhanced
green ﬂuorescent protein (EGFP) were obtained by poly-
merase chain reaction using the pcDNA3.1-hTERTC27 and
pEGFP-N2 (BD Biosciences) as templates, respectively. The
hTERTC27 cDNA was subcloned into the pEgr plasmid at
Kpn I and EcoR I sites to generate the pEgr-1-hTERTC27
plasmid (pEgr-C27). EGFP cDNA was then subcloned into
the pEgr-C27 plasmid at EcoR I and Xba I sites to generate a
pEgr-C27-GFP plasmid coexpressing hTERTC27 and GFP
fusion protein. C666-1 cells were transfected with the pEgr,
pEgr-C27, or pEgr-C27-GFP vectors using a Lipofectamine
2000 transfection reagent (Invitrogen), following the manu-
facturer’s instructions, and selected using 600 lg/mL G418
(Merck) for 2 weeks. The cells stably transfected with the
pEgr, pEgr-C27, or pEgr-C27-GFP vectors were called as
C666-Con cells, C666-C27 cells, or C666-C27-GFP cells, re-
spectively, and the unstransfected C666-1 cells were called as
C666-Mock cells.
Detection of EGFP
About 2· 106 C666-C27-GFP cells were seeded in 10-cm
dishes. After 12 hours of incubation, the cells were treated
with different concentrations (in lg/mL) of 5-FU (Sigma) of
0, 3.12, 6.25, 12.5, 25, respectively, for 48 hours. The cells
were imaged with a ﬂuorescence microscope (Zeiss). Then,
cells were washed with phosphate-buffered saline (PBS)
twice, harvested by trypsinization, and ﬁxed in 70% ethanol.
GFP expression was further determined by a ﬂow cytometry
analysis (Becton Dickinson).
Immunoblotting analysis
Cells were lyzed in an NP-40 lysis buffer containing
50mM Tris (pH 7.4), 150mM NaCl, 1% NP-40, 20lg/mL
PMSF, 1lg/mL pepstatin A, and 1lg/mL leupeptin (pH 7.4).
Tumor tissue was homogenized in 250mM sucrose contain-
ing 1mM ethylenediaminetetraacetic acid, 20lg/mL PMSF,
1lg/mL pepstatin A, and 1lg/mL leupeptin (pH 7.4) with
a glass Dounce homogenizer. Total protein was assayed us-
ing a DC protein assay kit (BioRad). Proteins (30 lg) were
electrophoresed through 12% (w/v) polyacrylamide and 1%
(w/v) sodium dodecyl sulfate gels. Proteins were transferred
from the gels by blotting onto a nitrocellulose membrane
(Millipore). The membranes were blocked with 0.02mol/L
Tris–HCl (pH 7.0), 0.9% (w/v) NaCl, and 0.1% (v/v) Tween-
20 containing 5% (w/v) nonfat milk for 1 hour at room
temperature. Antibodies against the hTERT COOH-terminal
fragment (1:250; Santa Cruz Biotechnology), cleaved caspase-
3 (1:1000; Cell Signaling Technology), cleaved caspase-9
(1:1000; Cell Signaling Technology), cleaved PARP (1:1000;
Cell Signaling Technology), and Bcl-2 (1:500; Santa Cruz
Biotechnology) were added and incubated overnight at 4C.
Bound antibodies were located by a further incubation with
horseradish peroxidase-conjugated goat anti-rabbit IgG
(1:5000; Santa Cruz Biotechnology). b-actin (1:500; Santa
Cruz Biotechnology) was used as a loading control. Blots
were developed with an ECL Plus kit (Pierce) and exposed to
Kodak ﬁlms.
Determination of the 50% inhibitory concentration
About 2 · 103 C666-Mock, C666-Con, or C666-C27 cells
were seeded in a 96-well plate. Twelve hours later, the cells
were treated with different concentrations (in lg/mL) of
5-FU of 0, 0.78, 1.56, 3.12, 6.25, 12.5, 25, 50, 100, 200, or 400,
respectively. An MTT assay was performed 48 hours later.
Brieﬂy, 20lL of 5mg/mL MTT (Sigma) in PBS was added,
and the cells were then incubated for 4 hours at 37C with
5% CO2. Cells were washed twice with PBS, and the pellet
was then solubilized in 150 lL of 100% dimethyl sulfoxide
(Sigma) by shaking for 5 minutes. Absorbance was measured
on a microplate reader (BioRad) at a wavelength of 570 nm.
The inhibitory rate (IR) and 50% inhibitory concentration
(IC50) were calculated using Origin 7.5 software package.
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Cell growth and proliferation assay
C666-Con or C666-C27 cells were seeded in six-well plates
(2.5 · 104/well) and a 96-well plate (1.0 · 104/well). Twelve
hours later, the cells were treated with PBS or 5-FU (6.25 or
12.5 lg/mL), respectively. Forty-eight hours later, cells in six-
well plate were imaged with a light microscope (Zeiss) and
then washed with PBS twice, harvested by trypsinization,
and counted using a hemocytometer (Shanghai Jinghong
Corporation). Cell proliferation in a 96-well plate was mea-
sured by the MTT assay as described above.
Colony formation assay
C666-Con or C666-C27 cells (5· 102/well) were seeded in
six-well plates. Twelve hours later, cells were exposed to
PBS, 6.25, or 12.5 lg/mL 5-FU for 48 hours and allowed to
grow for 14 days, ﬁxed with methanol for 10 minutes, and
stained with Giemsa for 15 minutes. The plates were washed
and dried, and the colonies were counted. All experiments
were done in triplicate.
Flow cytometry analysis of apoptosis
For quantitative analysis of apoptosis, cells were har-
vested at 48 hour after treating with 5-FU, washed once with
ice-cold PBS, incubated with annexin V-ﬂuorescein/PI
(Boehringer Mannheim) in a calcium-containing HEPES
(Sigma) buffer, and then immediately analyzed with a ﬂow
cytometry machine (Becton Dickinson).
TUNEL assay
The presence of apoptotic cells in the C666-1 cells was
detected by the terminal deoxynucleotidyl transferase-
mediated dUTP nick-end-labeling (TUNEL) assay using
the in situ cell death detection kit (POD; Roche), according to
the procedures recommended by the manufacturer. The ap-
optotic cells were analyzed under a ﬂuorescence microscope.
Tumor xenograft formation and histological analysis
BALB/C nude mice at 6 weeks of age were purchased
from the Medical Laboratory Animal Center of Guangdong
Province, China. Mice were injected with 100 lL (5 · 107
cells/mL in PBS) of C666-Con cell suspension (12 mice) or
C666-C27 cell suspension (12 mice) subcutaneously into the
mid-back region. One week after injection, the mice inocu-
lated with C666-Con or C666-C27 cells were randomized into
two groups, respectively (Con, Con + 5-FU and C27, C27 +
5-FU). Mice were administrated (i.p.) either saline or 5-FU
(40mg/kg daily, three times a day) for 5 days. Tumor
xenograft formation was measured on a daily base to make
the growth curves. At the end of the treatment, mice were
sacriﬁced. Tumor xenografts were surgically dissected,
weighed, measured and then ﬁxed with 4% formaldehyde in
PBS, and embedded in parafﬁn. Sections were stained with
hematoxylin and eosin (HE staining). The tumor volume was
calculated according to the equation L ·W2/2 with the
length (mm) being the longest axis of the tumor. This study
was carried out in strict accordance with the recommenda-
tions in the Guide for the Care and Use of Laboratory
Animals of the Medical Laboratory Animal Center of
Guangdong Province, China (the permit number is
SCXK2008-0002).
Statistical analysis
All data were presented as mean – SD. The results were
compared by an analysis of variance. All statistical calcula-
tions were performed with SPSS 11.0 software package. A
p-value< 0.05 was regarded as statistically signiﬁcant differ-
ence.
Results
5-FU increased hTERTC27-GFP expression driven
by Egr-1 promoter in C666-1 cells
We ﬁrstly constructed the pEgr-C27-GFP plasmid, in
which a cDNA-encoding hTERTC27-GFP fusion protein was
put at downstream of Egr-1 promoter. A ﬂuorescence mi-
croscopic assay showed the hTERTC27-GFP fusion protein
was expressed in pEgr-C27-GFP stably transfected C666 cells
(Fig. 1A). About 3.12lg/mL 5-FU obviously increased the
expression of hTERTC27-GFP fusion protein assayed by
ﬂow cytometry ( p< 0.01, Fig. 1B). With the increase of 5-FU
FIG. 1. 5-FU activated Egr-1
promoter to increase hTERTC27-GFP
expression in C666-1 cells. (A)
hTERTC27-GFP expression was
observed under the ﬂuorescence
inverse microscope. Scale bar = 200lm.
(B) hTERTC27-GFP expression levels
induced by 5-FU determined using a
ﬂow cytometry analysis. (C) Relative
hTERTC27-GFP expression levels in
C666-C27-GFP cells with or without
5-FU treatment. Values are means –
SD, n= 6; *p < 0.01 versus group
without 5-FU treatment. (D) Western
blot analysis of C666-C27-GFP cells
with or without 5-FU treatment using
corresponding antibodies against the
hTERT COOH-terminal polypeptide.
Actin was probed with an anti-actin
antibody as a loading control. 5-FU,
5-ﬂurorouracil.
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dosage, hTERTC27-GFP expression was increased up to
7.21-fold ( p < 0.01, Fig. 1C), which was conﬁrmed by the
Western blot analysis (Fig. 1D). The results indicate that 5-FU
can increase hTERTC27 expression by activating the Egr-1
promoter.
hTERTC27 increased sensitivity
of C666-1 cells to 5-FU
To examine the effect of overexpressed hTERTC27 on the
survival of 5-FU-treated C666-1 cells, growth inhibitions of
C666-Mock, C666-Con, or C666-C27 cells were analyzed
with the MTT assay after treatment with various concentra-
tions of 5-FU for 48 hours. We found that C666-C27
cells showed a lower proliferation ability than C666-Con cells
and C666-Mock cells. The IC50 of 5-FU in C666-C27 cells
(15.11 – 0.92 lg/mL) was signiﬁcantly lower than those in
C666-Mock cells (22.88 – 2.45 lg/mL) and C666-Con cells
(21.31 – 1.91 lg/mL) ( p < 0.05). IRs of cells were not signiﬁ-
cantly different between C666-Mock cells and C666-Con cells
(Fig. 2). These results indicate that overexpressed hTERTC27
makes the C666-1 cells more sensitive to 5-FU treatment.
Overexpressed hTERTC27 and 5-FU
synergistically inhibited C666-1 cell growth
The synergistic effect of the overexpressed hTERTC27
polypeptide and 5-FU on C666-1 cell proliferation was de-
termined by the MTT assay. As shown in Figure 3A and B,
cell proliferation was signiﬁcantly inhibited in group C27
( p < 0.05) and groups 5-FU ( p< 0.01) when compared with
that in group control. Interestingly, groups C27+ 5-FU
demonstrated lower cell proliferation rates than group C27
( p < 0.01) and groups 5-FU ( p < 0.01). Consistently, colony
formation assay showed that the colony formation rate in
group C27 (71.67 – 6.50%) was signiﬁcantly lower than that
in group control (95.00% – 7.23%) as showed in Figure 3C
and D ( p < 0.05). Moreover, the combined therapeutic group
of C27 + 6.25 lg/mL 5-FU (0.33%– 0.10%) demonstrated a
further decrease in the colony formation rate when compared
with groups C27 (71.67%– 6.50%, p< 0.01) or 6.25lg/mL
5-FU (8.33% – 2.95%, p< 0.01) alone. There was not any col-
ony found in group 12.5 lg/mL 5-FU only and group
12.5 lg/mL 5-FU+C27 (Fig. 3C, D). These results indicate
that overexpressed hTERTC27 and 5-FU synergistically in-
hibited the proliferation of C666-1 cells.
Overexpressed hTERTC27 and 5-FU synergistically
induce apoptosis in C666-1 cells
To determine if overexpressed hTERTC27 and 5-FU cause
apoptosis of C666-1 cells, the early apoptotic death
(AnneV +/PI- ) was assessed by ﬂow cytometry. As shown
in Figure 4A and B, the apoptotic death in group C27
FIG. 2. hTERTC27 increased sensitivity of C666-1 cells to
5-FU. (A) Dose–response curves of inhibitory effect of 5-FU on
C666-Mock, C666-Con, or C666-C27 cells. Cells were seeded
into 96-well plates. Twelve hours later, cells were treated with
the indicated concentrations of 5-FU for 48 hours. The inhib-
itory rate was measured by the MTT assay. (B) IC50 values
from the MTT assay. Values are means– SD, n= 6; *p< 0.05
versus group mock; :p< 0.05 versus group control.
FIG. 3. hTERTC27 and 5-FU
synergistically inhibited C666-1 cell
growth. (A) Representative pictures
showing C666-Con or C666-C27 cells
treated with 6.25 or 12.5 lg/ml 5-FU
for 48 hours. Scale bar= 200 lm. (B)
Effects of hTERTC27 and 5-FU on
C666-1 cell proliferation measured by
the MTT assay. (C) Representative
pictures of colony formation assay. (D)
Colony formation rates. All values are
means – SD, n = 6; *p < 0.01 versus
group control; :p < 0.05 versus group
control; p < 0.01 versus group C27;
6p < 0.01 versus group 6.25 lg/mL
5-FU; )p< 0.01 versus group 12.5 lg/
mL 5-FU.
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(7.41% – 1.81%) was signiﬁcantly increased compared to that
in group control (2.43% – 0.37%, p< 0.01). Further, group
C27 + 6.25 lg/mL 5-FU (15.77% – 3.98%) demonstrated a sig-
niﬁcant increase in the apoptotic death compared to group
C27 ( p < 0.01) and group 6.25 lg/mL 5-FU (10.34% – 2.07%,
p < 0.05), and this trend of difference was also found between
group C27+ 12.5 lg/mL 5-FU (35.15% – 5.66%) and group
12.5 lg/mL 5-FU (26.32% – 4.12%). To conﬁrm this result, the
TUNEL assay was performed (Fig. 4C, D). It was found that
*9.11% C666-1 cells were TUNEL positive in group C27,
which is signiﬁcantly higher than control (about 3.27%,
p < 0.01). However, about 36.73% and 61.65% C666-1 cells
were TUNEL positive in groups C27 + 6.25 lg/mL 5-FU and
C27 + 12.5 lg/mL 5-FU, respectively, whereas only about
24.34% and 44.14% C666-1 cells were under apoptosis in
groups 6.25 lg/mL 5-FU and 12.5 lg/mL 5-FU. The apoptotic
rates of C666-1 cells in combined therapeutic groups were
remarkably higher than groups C27 ( p< 0.01) and 5-FU
( p< 0.05). These data suggest that overexpressed hTERTC27
driven by Egr-1 promoter and 5-FU synergistically promotes
the C666-1 cell apoptosis.
5-FU-induced hTERTC27 polypeptide
and 5-FU synergistically inhibited the growth
of NPC tumor in vivo
BALB/C mice were injected subcutaneously with C666-
Con cells or C666-C27 cells, respectively. A week after
injection, animals were treated with 40mg/kg 5-FU daily,
and tumor growth was monitored for 5 days. As shown in
Figure 5A, tumor growth was signiﬁcantly inhibited by the
hTERTC27 polypeptide and 5-FU. The tumor volume and
weight in groups C27 and 5-FU were signiﬁcantly dimin-
ished compared with those in group control (Fig. 5A–C,
p < 0.05). Furthermore, the volume and weight of tumor in
group C27+ 5-FU were signiﬁcantly lower than in groups
C27 and 5-FU (Fig. 5B, C, p< 0.05). In addition, local muscle
inﬁltration was found in all mice of group control, whereas
local muscle inﬁltration was found in only 67.00% of group
C27 mice, 50.00% of group 5-FU mice, and 16.70% of group
C27 + 5-FU mice, respectively (Fig. 5D).
5-FU-induced hTERTC27 polypeptide and 5-FU
promote the cleavage of poly(ADP-ribose)
polymerase, the activation of caspases,
and down regulation of Bcl-2
It is well known that apoptosis is characterized by the
cleavage of poly(ADP-ribose) polymerase (PARP) and acti-
vation of caspases. Thus, we examined the effect of
hTERTC27 and 5-FU on the cleavage of PARP and the acti-
vation of caspases. As shown in Figure 6A and B, the amount
of PARP cleavage was markedly enhanced in group C27+5-FU
when compared to that in group 5-FU. Similar results
were also observed in the activation of caspases (Fig. 6A, B).
These results consistently showed that the combination of
hTERTC27 and 5-FU synergistically induced apoptotic death
in NPC tumors. Then, we evaluated changes in the signaling
proteins of the mitochondrion-dependent apoptotic path-
way. Bcl-2 is a very important protein of the antiapoptotic
family. As shown in Figure 6C and D, the Bcl-2 expression in
groups C27 and 5-FU remarkably decreased in comparison
with that in group control. Further, the Bcl-2 expression in
group C27 + 5-FU diminished obviously when compared
with that in groups C27 or 5-FU.
Discussion
The motivation of this study was to determine if the Egr-1
promoter can be activated by 5-FU to increase hTERTC27
expression, and if 5-FU can be used as an inducer to increase
Egr-promoter-driven hTERTC27 polypeptide overexpression
and a chemotherapeutic agent on NPC cancer. Our results
showed the Egr-1 promoter, which is sensitive to reactive
FIG. 4. Synergistic effects of
hTERTC27 and 5-FU on apoptosis in
C666-1 cells. (A) Apoptosis in C666-1
cells transfected with the pEgr vector
or pEgr-C27 without or with 6.25 or
12.5 lg/mL 5-FU for 48 hours.
Apoptosis was determined using an
Annexin V-PI double-staining ﬂow
cytometric technique. (B) Percentages
of early apoptosis from experiments
showed in (A). (C) Representative
ﬁelds of the TUNEL assay; scale
bar = 400 lm. (D) Percentages of
TUNEL-positive cells from
experiments showed in (C). All values
are means – SD, n = 6; *p< 0.01 versus
group control; p < 0.01 versus group
C27; 6p < 0.05 versus group 6.25 lg/
mL 5-FU; )p < 0.05 versus group
12.5 lg/mL 5-FU.
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oxygen intermediates,18 was activated by 5-FU to drive
hTERTC27 overexpression. At appropriate concentrations of
5-FU, we observed the synergistic antitumor effect of the
hTERTC27 polypeptide regulated by the Egr-1 promoter and
5-FU on nasopharyngeal carcinoma.
As we know, 5-FU is one of the most widely used drugs in
NPC chemotherapy1,2 because it can effectively inhibit the
activity of thymidylate synthase, block the DNA synthesis,
arrest the cell cycle, and promote apoptosis. However, the
severe side effects of 5-FU and its limited sensitivity to cancer
cells still bring great obstacles to cancer therapy. Different
strategies have been designed to decrease the dosage and
increase the antitumor sensitivity of 5-FU. Therefore, it is
very important to combine 5-FU chemotherapy and gene
therapy to make the tumor cells sensitive to 5-FU treatment
and enhance its antitumor effects.19–21
FIG. 5. In vivo synergistic antitumor
effect of hTERTC27 and 5-FU on
nasopharyngeal carcinoma tumor. (A)
Tumor growth curves in C666-1
cell-transplanted mice. Tumors were
measured in three dimensions on the
indicated days after treatment with
40mg/kg 5-FU. Values are means –
SD, n = 6; *p < 0.05. (B) Images of
tumors. Scale bar = 10mm. (C)Weights
of xenograft tumors at day 5
post-treatment. Values are means – SD,
n = 6; :p< 0.05 versus group control;
*p < 0.01 versus group control; p< 0.05
versus group C27; 6p < 0.05 versus
group 5-FU. (D) Hematoxylin and eo-
sin staining, indicating the local muscle
inﬁltration (arrow) in tumors. Scale
bar = 200lm.
FIG. 6. Immunoblotting analysis of
cleaved PARP, caspases, and Bcl-2
protein. (A) Immunoblotting analysis
for cleaved PARP and caspases in
tumor tissues after treatment. Actin
was probed as loading controls. (B)
Quantiﬁcation of cleaved PARP and
caspases in tumor tissues. Values are
means – SD, n= 3; *p < 0.01 versus
group control; ,p< 0.01 versus group
C27; 6p < 0.05 versus group 5-FU. (C)
Representative immunoblotting
analysis of Bcl-2 in tumor tissues. (D)
Quantiﬁcation of the Bcl-2 expression
in tumor tissues. Values are means –
SD, n= 3; *p < 0.01 versus group
control; :p< 0.05 versus group control;
p < 0.01 versus group C27; 6p< 0.01
versus group 5-FU. PARP,
poly(ADP-ribose) polymerase.
SYNERGISTIC ANTITUMOR EFFECT OF HTERTC27 AND 5-FU 439
Recently, a variety of therapeutic approaches are being
investigated to target telomere or telomerase, since many
tumors express high levels of telomerase.6,22–24 We have
newly constructed the hTERTC27 polypeptide and previ-
ously reported that this polypeptide rendered the HeLa cells
more sensitive to H2O2 treatment. Moreover, our previ-
ous study showed that overexpressed hTERTC27 induced
telomere dysfunction in HeLa cells and inhibits cervical
carcinoma and glioblastoma tumor growth and tumor-
igenicity.16–18 However, hTERTC27 gene therapy alone can-
not quickly inhibit the tumor growth because of its limited
expression level. Here, our results showed that hTERTC27
remarkably inhibited cell proliferation, promoted apoptosis
of C666-1 cells in vitro, and obviously slowed down the NPC
tumor growth in vivo as well. The IC50 value of 5-FU in
hTERTC27-overexpressed NPC cells was signiﬁcantly lower
than that in control cells, which indicated that a low con-
centration of 5-FU treatment in combination with hTERTC27
polypeptide achieves the same antitumor effect as a higher
5-FU concentration. This strategy can decrease the thera-
peutic dosage and the side effects of 5-FU.
To further optimize the therapeutic strategy of the
hTERTC27 gene therapy and 5-FU chemotherapy, we intro-
duced the Egr-1 promoter as a bridge to amplify the anti-
tumor effect of hTERTC27 and 5-FU. The Egr-1 promoter
increased hTERTC27 expression in NPC cells due to reactive
oxygen intermediates caused by 5-FU, and the high expres-
sion of hTERTC27 rendered the cells more sensitive to 5-FU
and made the cells generate more reactive oxygen interme-
diates and further led to a higher hTERTC27 protein level. By
recycling, the combined therapy of hTERTC27 driven by
Egr-1 promoter and 5-FU exerted a more efﬁcient antitumor
effect just as found in our study. Also, the combined treat-
ment of hTERTC27 and 5-FU signiﬁcantly promoted apo-
ptosis in C666-1 cells. An in vivo mouse model also showed
that hTERTC27 driven by the Egr-1 promoter and 5-FU
synergistically inhibited tumor growth and local inﬁltration.
The Bcl-2 family proteins have been shown to play im-
portant roles in apoptotic cell death.25 Bcl-2 inhibits cell
apoptosis. Here, we found that Bcl-2 expression was ob-
viously diminished in tumors of combined treating group.
Caspase-3 and caspase-9 are involved in cell apoptosis. A
classical substrate of activated caspases is PARP, which is a
DNA-repair enzyme needed for normal cells.26 Interest-
ingly, we found that obviously elevated activated caspase-3
and 9 expressions and cleaved PARP with combined
therapy of C27 and 5-FU. These results conﬁrmed the
synergistic antitumor effects of the hTERTC27 polypeptide
driven by Egr-1 promoter and 5-FU on nasopharyngeal
carcinoma.
In summary, 5-FU activated the Egr-1 promoter to over-
express hTERTC27 polypeptide, which enhanced the sensi-
tivity of NPC cells to 5-FU treatment. Our study proposes
that the combinational therapy of 5-FU-Egr-1-hTERTC27 is
adaptable to treating nasopharyngeal cancer.
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